CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
CTMX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
CytomX Therapeutics, Inc.NASDAQ: CTMX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $19.24M rose 2.0% year over year, ahead of the -13.8% change in trailing-twelve-month research & development. Sequentially, it fell 9.4% from the prior quarter. Over 3 fiscal years it compounded at -14.9% a year.
Context
- Research & development amounted to 90.2% of revenue in FY2025, up 29.8 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +2.0% holds above the trailing-twelve-month pace of -13.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 68.73M USD
- Year-over-year change
- -17.6%
- 4-year CAGR
- -11.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 68.73M | -17.6% |
| FY2024 | 2024-12-31 | 83.38M | +7.3% |
| FY2023 | 2023-12-31 | 77.68M | -30.4% |
| FY2022 | 2022-12-31 | 111.65M | -2.2% |
| FY2021 | 2021-12-31 | 114.19M | — |
Research & Development vs competitors
How CTMX compares with its peers on the latest reported figures
- CTMX's LTM Mar 2026 research & development of $69.1M is the 9th highest of the 10 companies compared; the peer median is $151.37M.
- Its year-over-year change of -13.8% is the 6th highest of 9, against a peer median of +10.8%.
- Research & development amounts to 194.4% of revenue for CTMX, versus a peer median of 243.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.51B | +1655.5% | -13.1% | 942.7% | |
| LTM Aug 2026 | $331.95M | +10.2% | +18.6% | 47.3% | |
| LTM Sep 2026 | $283.32M | +31.2% | +43.9% | 252960.7% | |
| LTM Jun 2026 | $255.77M | +11.4% | +6.3% | 243.6% | |
| LTM Mar 2026 | $151.37M | -38.7% | +6.7% | 152.0% | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $94.95M | -15.8% | -17.7% | 119.9% | |
| LTM Mar 2026 | $76.25M | +21.5% | -5.1% | 550.2% | |
| LTM Mar 2026 | $69.1M | -13.8% | -14.9% | 194.4% | |
| LTM Jun 2024 | $30.07M | — | -35.3% | 3686.7% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CTMX) | $151.37M | +10.8% | -5.1% | 243.6% | |
Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 114.19M | 111.65M | 77.68M | 83.38M | 68.73M |
| Selling, General & Admin | 39.16M | 42.85M | 30.02M | 29.73M | 29.84M |
| Operating Expenses | 153.35M | 154.5M | 107.7M | 113.11M | 98.57M |
| Depreciation & Amortization | 2.71M | 2.44M | 2.18M | 1.77M | 1.38M |
| EBITDA | (113.16M) | (96.87M) | 5.5M | 33.86M | (15.75M) |
| EBITDA Margin | -303.3% | -182.2% | 5.4% | 24.5% | -20.7% |
| Operating Income | (116.04M) | (101.34M) | (6.48M) | 25M | (22.36M) |
| Operating Margin | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Interest Income | 255K | 1.68M | 9.84M | 7.14M | 5.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 172K | 2.02M | 9.81M | 7.1M | 5.23M |
| Income Before Tax | (115.87M) | (99.32M) | 3.32M | 32.09M | (17.13M) |
| Pre-Tax Margin | -310.5% | -186.8% | 3.3% | 23.2% | -22.5% |
| Income Tax Expense | 0 | 0 | 3.89M | 224K | 238K |
| Net Income | (115.87M) | (99.32M) | (569K) | 31.87M | (17.37M) |
| Net Margin | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| EPS (Basic) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| EPS (Diluted) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| Weighted Avg Shares | 64.15M | 65.74M | 73.81M | 84.44M | 137.94M |
| Weighted Avg Shares (Diluted) | 64.15M | 65.74M | 73.81M | 84.75M | 137.94M |
CytomX Therapeutics, Inc.
NASDAQ:CTMX
Intrinsic Alpha fair value
Locked
Current Price
$1.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.